Dapagliflozin attenuates myocardial remodeling in hypertension by activating the circadian rhythm signaling pathway

[1]  Jianlin Du,et al.  Transcriptomic profile analysis of the left atrium in spontaneously hypertensive rats in the early stage , 2022, Frontiers in Pharmacology.

[2]  M. Dörr,et al.  Myeloid differentiation factor‐2 activates monocytes in patients with dilated cardiomyopathy , 2022, Immunology.

[3]  Jianlin Du,et al.  The Relationship between Abnormal Circadian Blood Pressure Rhythm and Risk of Readmission in Patients with Heart Failure with Preserved Ejection Fraction , 2021 .

[4]  Zhan Ye,et al.  Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols , 2020, RNA.

[5]  Jianlin Du.  Risk of Target Organ Damage in Patients with Masked Hypertension versus Sustained Hypertension: A Meta-analysis , 2020 .

[6]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[7]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[8]  E. Sanidas,et al.  Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension. , 2019, American journal of hypertension.

[9]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[10]  S. Terra,et al.  Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials , 2019, Cardiovascular Diabetology.

[11]  Fen Li,et al.  Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload , 2019, American journal of hypertension.

[12]  L. V. Van Laake,et al.  Circadian rhythms and the molecular clock in cardiovascular biology and disease , 2019, Nature Reviews Cardiology.

[13]  K. Connelly,et al.  Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction , 2019, JACC. Basic to translational science.

[14]  Halina Dobrzynski,et al.  Circadian rhythm of cardiac electrophysiology, arrhythmogenesis, and the underlying mechanisms , 2019, Heart rhythm.

[15]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[16]  K. Kario,et al.  Twenty-Four-Hour Blood Pressure–Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension , 2018, Circulation.

[17]  K. Kario,et al.  24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study. , 2018, Circulation.

[18]  N. Fukuda,et al.  The adrenal gland circadian clock exhibits a distinct phase advance in spontaneously hypertensive rats , 2018, Hypertension Research.

[19]  A. Nakashima,et al.  Dec1 and CLOCK Regulate Na+/K+-ATPase &bgr;1 Subunit Expression and Blood Pressure , 2018, Hypertension.

[20]  A. Nishiyama,et al.  The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity , 2018, Front. Endocrinol..

[21]  S. Chon,et al.  Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial , 2018, Diabetes, obesity & metabolism.

[22]  A. Vaag,et al.  MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? , 2018, European journal of endocrinology.

[23]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[24]  I. Tikkanen,et al.  Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension , 2017, Diabetes, obesity & metabolism.

[25]  S. Verma,et al.  Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure , 2017, JACC. Basic to translational science.

[26]  A. Kengne,et al.  Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients , 2017, Journal of the American Heart Association.

[27]  I. J. Lynch,et al.  Desoxycorticosterone pivalate‐salt treatment leads to non‐dipping hypertension in Per1 knockout mice , 2017, Acta physiologica.

[28]  Dave L Dixon,et al.  Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.

[29]  A. Nishiyama,et al.  Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats , 2017, Clinical and experimental pharmacology & physiology.

[30]  F. Alibhai,et al.  Disrupting the key circadian regulator CLOCK leads to age-dependent cardiovascular disease. , 2017, Journal of molecular and cellular cardiology.

[31]  Joseph S. Takahashi,et al.  Transcriptional architecture of the mammalian circadian clock , 2016, Nature Reviews Genetics.

[32]  M. Al-Omran,et al.  Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? , 2016, Diabetes Care.

[33]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[34]  M. Elisaf,et al.  Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors , 2016, Expert opinion on pharmacotherapy.

[35]  Yoshiya Tanaka,et al.  A Case of Type 2 Diabetes with a Change from a Non-Dipper to a Dipper Blood Pressure Pattern by Dapagliflozin. , 2016, Journal of UOEH.

[36]  A. Nishiyama,et al.  A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats , 2016, Hypertension Research.

[37]  Michelle L. Gumz,et al.  Transcriptional regulation of NHE3 and SGLT1 by the circadian clock protein Per1 in proximal tubule cells. , 2015, American journal of physiology. Renal physiology.

[38]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[39]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[40]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[41]  Jacob Richards,et al.  Clock genes in hypertension: novel insights from rodent models , 2014, Blood pressure monitoring.

[42]  I. Tikkanen,et al.  Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.

[43]  Hong-Xia Wang,et al.  NADPH oxidases mediate a cellular "memory" of angiotensin II stress in hypertensive cardiac hypertrophy. , 2013, Free radical biology & medicine.

[44]  Chao-shu Tang,et al.  Role for granulocyte colony stimulating factor in angiotensin II-induced neutrophil recruitment and cardiac fibrosis in mice. , 2013, American journal of hypertension.

[45]  D. de Zeeuw,et al.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[46]  Hui-Hua Li,et al.  Carboxyl terminus of heat shock protein 70-interacting protein inhibits angiotensin II-induced cardiac remodeling. , 2012, American journal of hypertension.

[47]  D. Duncker,et al.  Apelin Enhances Cardiac Neovascularization After Myocardial Infarction by Recruiting Aplnr+ Circulating Cells , 2012, Circulation research.

[48]  Günter P. Wagner,et al.  Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples , 2012, Theory in Biosciences.

[49]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[50]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[51]  Ruiqiang Li,et al.  SOAP: short oligonucleotide alignment program , 2008, Bioinform..

[52]  H. Abdi.  The Bonferonni and Šidák Corrections for Multiple Comparisons , 2006 .

[53]  E. Nishida,et al.  Involvement of the MAP kinase cascade in resetting of the mammalian circadian clock. , 2000, Genes & development.

[54]  S. Izumo,et al.  Calcineurin—the missing link in cardiac hypertrophy , 1998, Nature Medicine.

[55]  B. A. Harder,et al.  Signaling pathways in cardiac myocyte hypertrophy. , 1997, Journal of molecular and cellular cardiology.

[56]  E. Nishida,et al.  Involvement of the MAP kinase cascade in Xenopus mesoderm induction. , 1995, The EMBO journal.

[57]  P. Poole‐Wilson,et al.  Cellular mechanisms of cardiac hypertrophy. , 1995, British heart journal.